الصفحة 1 من عند 34 النتائج
Patients with alcohol use disorder (AUD) are susceptible to a variety of medical, psychiatric, and social complications, and utilize acute health services frequently; the prevalence of hospitalized patients with AUD is estimate to be between 16% and 26%. While the treatment for the acute
Alcohol withdrawal syndrome AWS (Alcohol Withdrawal Syndrome), is defined as the appearance of two or more data of autonomic hyperactivity, nausea, hallucinations and seizures associated with cessation of alcohol consumption. For its evaluation, the CIWA-Ar (Clinical Institute Withdrawal Assessment
In 2014, the estimated population who were suffering from drug abuse and drug-related disorders reached over 29 million worldwide, making it a global health challenge. Moreover, 43.5 per million people die annually from associated drug use. According to the United Nations Office on Drugs and Crime
MATERIALS AND METHODS
After approval of the institutional Ethics committee board, written informed consent will be taken from all the eligible and willing patients.
A. Study design: Randomized double blind active controlled parallel group noninferiority clinical trial.
B. Randomization: A variable
This is a randomized control trial of the impact of mindfulness meditation in patients with known diagnosis of epilepsy over the course of 2 years.
Participating physicians will recruit patients meeting the inclusion and exclusion criteria who have been diagnosed and treated in the epilepsy clinic
Alcohol use disorder is a common comorbidity among trauma patients. This pre-existing condition is associated with Alcohol Withdrawal Syndrome (AWS) and frequently complicates the management of this patient population. Current treatment and/or prevention of AWS includes the administration of
Alcohol withdrawal syndrome (AWS) is a frequent and potentially fatal outcome. It is crucial to treat AWS in order to reduce symptoms severity, to prevent severe complications and to increase patient motivation to maintain long-term alcohol abstinence. Clarify the relevance of oral magnesium
This is an open-label Phase IIa pilot study of the tolerability and effects on binge drinking of bupropion and naltrexone for binge drinkers.
Participants: Investigators will recruit 12 men or women ages 21-34 years who exhibit a minimum of 5/3 (men/women) or more binge drinking episodes per month
The study will be conducted on patients with alcohol dependence admitted or coming to the out patient department. The enrolled subjects will be divided into two groups randomly using computer generated randomization system. Informed consent shall be taken from the patient/nearest relative of the
Inclusions are performed by any previously-labeled baclofen-prescribing physician in the Hauts-de-France or Normandie French regions.
INITIAL ASSESSMENT PHONE CALLS
In the 15 days following the inclusion, participants will receive two successive phone calls. The first call will be performed by a
Sudden unexpected death in epilepsy (SUDEP) primarily affects young adults with drug-resistant epilepsy, with an incidence of about 0.4%/year. The diagnosis of SUDEP requires that anamnestic data and post-mortem examination do not reveal a structural or toxicological cause for death. Generalized
Study Design This is a randomized, double blind, placebo-controlled early phase II clinical trial.
Recruitment: The study has 2 phases. The first is testing intranasal treatments (oxytocin [OT], placebo) on alcohol withdrawal (the inpatient phase) and the second is testing intranasal treatments on
1. HYPOTHESIS AND OBJECTIVES PEG-IFN as an immunomodulatory agent could potentiate the antiviral efficacy of patients on long term nucleos(t)ide analogue therapy and improve early indicators of efficacy, HBeAg loss and reduction in qHBsAg. This study will also test whether add-on compared to switch
Objectives:
- By comparing the two PET scans (before and after tiagabine) done in the same day, we can understand more about how much GABA your brain makes and about the activity of your GABA receptors in the brain.
Eligibility:
- Individuals 18-45 years of age who are heavy drinkers or healthy
B. The study follows a randomized controlled study design with division of approximately 60 individuals into 2 groups. The study group (n=30) will be called "Mindfulness Training for Smokers" (MTS) and will provide 7 weeks of mindfulness meditation instruction. The control group (n=30) will be